Pharmamarketeer

EMA’s safety committee recommends restriction on use of Lemtrada for multiple sclerosis patients

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) committee has recommended restrictions on the use of Lemtrada (alemtuzumab) in patients with relapsing remitting multiple sclerosis.

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl